KNG1 Protein (Transcript Variant 2) (Myc-DYKDDDDK Tag)

Catalog No. ABIN2724257

Product Details

Target: KNG1 (Kininogen 1 (KNG1))

Protein Type: Recombinant

Protein Characteristics: Transcript Variant 2

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This KNG1 protein is labelled with Myc-DYKDDDDK Tag.

Application: Antibody Production (AbP), Standard (STD)

Characteristics:

• Recombinant human Kininogen-1 (transcript variant 2) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Purity: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Application Details

Application Notes: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Comment:

The tag is located at the C-terminal.

Restrictions: For Research Use only

Handling

Concentration: 50 μg/mL

Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.

Storage: -80 °C

Storage Comment: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Target Details

Target: KNG1 (Kininogen 1 (KNG1))

Alternative Name: Kininogen-1 (KNG1 Products)

Synonyms: BDK Protein, BK Protein, KNG Protein, Kng Protein, KNG2 Protein, fb64g01 Protein, wu:fb64g01 Protein, zgc:103569 Protein, kininogen Protein, bdk Protein, kng Protein, KNG1 Protein, IHRP Protein, KINKG Protein, KINKH Protein, Kng1 Protein, Kngk Protein, kininogen 1 Protein, kininogen 1 L homeolog Protein, inter-alpha-trypsin inhibitor heavy chain family member 4 Protein, kininogen 2-like 1 Protein, KNG1 Protein, Kng1 Protein, kng1 Protein, kng1.L Protein, ITIH4 Protein, Kng2l1 Protein

Background: (1) Kininogens are inhibitors of thiol proteases (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action) (5) LMW-kininogen inhibits the aggregation of thrombocytes (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. [UniProtKB/Swiss-Prot Function]

Molecular Weight: 47.7 kDa

NCBI Accession: NP_000884

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process